ATAGI previously said the mRNA vaccine developed by Pfizer and BioNTech should be preferred for people aged under 60. It now says people in that age group living in an 'outbreak' area and unable to access that vaccine should have the option of the adenovirus viral vector vaccine developed by AstraZeneca and The University of Oxford.
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News

